Alfredo Carrato Selected Research

Pain (Aches)

1/2021	The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
1/2021	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alfredo Carrato Research Topics

Disease

68	Neoplasms (Cancer) 01/2024 - 01/2002
37	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023 - 08/2005
29	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 10/2002
18	Pancreatic Neoplasms (Pancreatic Cancer) 05/2024 - 01/2002
17	Adenocarcinoma 05/2024 - 08/2005
8	Carcinoma (Carcinomatosis) 01/2022 - 06/2007
7	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2008
7	Carcinogenesis 01/2021 - 07/2009
7	Colonic Neoplasms (Colon Cancer) 01/2019 - 06/2005
6	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2009
5	Neutropenia 02/2024 - 11/2004
5	Breast Neoplasms (Breast Cancer) 03/2023 - 06/2007
5	Renal Cell Carcinoma (Grawitz Tumor) 11/2022 - 09/2011
5	Chronic Pancreatitis 01/2022 - 03/2011
4	Stomach Neoplasms (Stomach Cancer) 01/2022 - 12/2005
4	Diarrhea 04/2013 - 03/2005
2	Thrombocytopenia (Thrombopenia) 02/2024 - 04/2013
2	COVID-19 03/2023 - 01/2022
2	Pain (Aches) 01/2021 - 01/2021
2	Circulating Neoplastic Cells 01/2021 - 10/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 06/2011
2	Hemorrhage 01/2019 - 07/2016
2	Anemia 07/2016 - 04/2013
2	Weight Loss (Weight Reduction) 06/2015 - 11/2004
2	Stomatitis 04/2013 - 09/2007
2	Hand-Foot Syndrome 04/2013 - 09/2007
2	Disease Progression 04/2013 - 06/2011
2	Febrile Neutropenia 04/2013 - 07/2009
2	Fatigue 04/2013 - 05/2011
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2011 - 03/2011
2	Genetic Predisposition to Disease (Genetic Predisposition) 02/2009 - 09/2006
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2009 - 11/2004
2	Rectal Neoplasms (Rectal Cancer) 07/2008 - 02/2008
1	Breakthrough Infections 03/2023

Drug/Important Bio-Agent (IBA)

17	Fluorouracil (Carac)FDA LinkGeneric 02/2024 - 06/2004
16	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2024 - 10/2002
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2008
12	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 06/2004
9	Leucovorin (Folinic Acid)FDA Link 02/2024 - 03/2005
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 06/2007
7	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 11/2004
7	DNA (Deoxyribonucleic Acid)IBA 10/2015 - 08/2006
7	erucylphosphocholineIBA 11/2012 - 01/2002
6	Gemcitabine FDA Link 02/2024 - 06/2011
6	Messenger RNA (mRNA)IBA 03/2023 - 06/2007
5	TrihalomethanesIBA 01/2022 - 01/2007
5	Drinking WaterIBA 01/2022 - 01/2007
5	Capecitabine (Xeloda)FDA Link 01/2022 - 06/2005
5	ORALIT (ORS)IBA 01/2019 - 04/2007
5	Sunitinib (Sutent)FDA Link 01/2017 - 06/2011
5	CarcinogensIBA 04/2012 - 07/2006
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2021 - 10/2006
4	SmokeIBA 01/2020 - 07/2006
4	Bevacizumab (Avastin)FDA Link 01/2019 - 02/2008
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2017 - 03/2011
4	AminesIBA 04/2012 - 07/2007
3	130-nm albumin-bound paclitaxelIBA 02/2024 - 01/2015
3	LigandsIBA 01/2024 - 10/2002
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2023 - 07/2009
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2011
3	EnzymesIBA 01/2021 - 02/2009
3	Phosphotransferases (Kinase)IBA 07/2020 - 03/2017
3	Trastuzumab (Herceptin)FDA Link 01/2020 - 08/2009
3	Transforming Growth Factor-beta Type I ReceptorIBA 11/2009 - 02/2009
3	Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA 10/2008 - 11/2003
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2008 - 10/2006
2	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2021
2	Genetic Markers (Genetic Marker)IBA 01/2023 - 10/2014
2	CollagenIBA 01/2023 - 01/2019
2	cabozantinibIBA 11/2022 - 06/2020
2	MicroRNAs (MicroRNA)IBA 04/2021 - 03/2019
2	Cytotoxins (Cytolysins)IBA 03/2021 - 03/2011
2	Tyrosine (L-Tyrosine)FDA Link 07/2020 - 04/2019
2	Formaldehyde (Formol)FDA Link 01/2020 - 08/2006
2	ParaffinIBA 01/2020 - 08/2006
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 12/2015
2	Panitumumab (Vectibix)FDA Link 01/2019 - 01/2017
2	Cetuximab (Erbitux)FDA Link 01/2018 - 01/2018
2	nintedanibIBA 03/2017 - 11/2014
2	Codon (Codons)IBA 12/2015 - 08/2007
2	discoidin-binding polysaccharideIBA 08/2013 - 11/2010
2	SolventsIBA 10/2010 - 01/2002
2	raltitrexed (D 1694)IBA 08/2009 - 10/2008
2	XELOXIBA 05/2009 - 09/2007
2	Epirubicin (Ellence)FDA LinkGeneric 01/2009 - 11/2004
1	peptidoglycan recognition proteinIBA 05/2024
1	RutheniumIBA 01/2024
1	Immunoglobulin G (IgG)IBA 03/2023
1	2019-nCoV Vaccine mRNA-1273IBA 03/2023
1	COVID-19 VaccinesIBA 03/2023
1	Neutralizing AntibodiesIBA 03/2023
1	Cyclin-Dependent Kinase 4IBA 03/2023
1	Culture MediaIBA 01/2023

Therapy/Procedure

27	Therapeutics 01/2022 - 12/2005
23	Drug Therapy (Chemotherapy) 01/2022 - 05/2005
4	Immunotherapy 01/2022 - 08/2019
4	Radiotherapy 01/2011 - 12/2005
3	Adjuvant Chemotherapy 01/2022 - 07/2008
3	Chemoradiotherapy 01/2018 - 07/2008
2	Gastrectomy 01/2022 - 07/2016